Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Department of Surgery, YanBian University Hospital, Yanji, Jilin, China.
Front Immunol. 2023 Jul 21;14:1187388. doi: 10.3389/fimmu.2023.1187388. eCollection 2023.
Securing a well-established mouse model is important in identifying and validating new therapeutic targets for immuno-oncology. The C57BL/6 mouse is one of the most fully characterised immune system of any animal and provides powerful platform for immuno-oncology discovery. An orthotopic tumor model has been established using TBP3743 (murine anaplastic thyroid cancer [ATC]) cells in B6129SF1 hybrid mice, this model has limited data on tumor immunology than C57BL/6 inbred mice. This study aimed to establish a novel orthotopic ATC model in C57BL/6 mice and characterize the tumor microenvironment focusing immunity in the model.
Adapted TBP3743 cells were generated via serial passaging in C57BL/6 mice. Subsequently, the following orthotopic tumor models were established via intrathyroidal injection: B6129SF1 mice injected with original TBP3743 cells (original/129), B6129SF1 mice injected with adapted cells (adapted/129), and C57BL/6 mice injected with adapted cells (adapted/B6).
The adapted TBP3743 cells de-differentiated but exhibited cell morphology, viability, and migration/invasion potential comparable with those of original cells . The adapted/129 contained a higher Ki-67 cell fraction than the original/129. RNA sequencing data of orthotopic tumors revealed enhanced oncogenic properties in the adapted/129 compared with those in the original/129. In contrast, the orthotopic tumors grown in the adapted/B6 were smaller, with a lower Ki-67 cell fraction than those in the adapted/129. However, the oncogenic properties of the tumors within the adapted/B6 and adapted/129 were similar. Immune-related pathways were enriched in the adapted/B6 compared with those in the adapted/129. Flow cytometric analysis of the orthotopic tumors revealed higher cytotoxic CD8 T cell and monocytic-myeloid-derived suppressor cell fractions in the adapted/B6 compared with the adapted/129. The estimated CD8 and CD4 cell fractions in the adapted/B6 were similar to those in human ATCs but negligible in the original/B6.
A novel orthotopic tumor model of ATC was established in C57BL/6 mice. Compared with the original B6129SF1 murine model, the novel model exhibited more aggressive tumor cell behaviours and strong immune responses. We expect that this novel model contributes to the understanding tumor microenvironment and provides the platform for drug development.
在鉴定和验证免疫肿瘤学的新治疗靶点方面,建立一个成熟的小鼠模型非常重要。C57BL/6 小鼠是所有动物中免疫系统研究最充分的一种,为免疫肿瘤学的发现提供了强大的平台。已经在 B6129SF1 杂交小鼠中使用 TBP3743(鼠间变性甲状腺癌[ATC])细胞建立了原位肿瘤模型,该模型在肿瘤免疫学方面的数据比 C57BL/6 近交系小鼠有限。本研究旨在建立一种新的 C57BL/6 小鼠原位 ATC 模型,并对该模型的肿瘤微环境进行免疫特征分析。
通过在 C57BL/6 小鼠中进行连续传代,生成适应性 TBP3743 细胞。随后,通过甲状腺内注射建立以下原位肿瘤模型:B6129SF1 小鼠注射原始 TBP3743 细胞(原始/129)、B6129SF1 小鼠注射适应性细胞(适应性/129)和 C57BL/6 小鼠注射适应性细胞(适应性/B6)。
适应性 TBP3743 细胞去分化,但具有与原始细胞相当的细胞形态、活力和迁移/侵袭能力。适应性/129 的 Ki-67 细胞分数高于原始/129。原位肿瘤的 RNA 测序数据显示,与原始/129 相比,适应性/129 具有增强的致癌特性。相比之下,在适应性/B6 中生长的原位肿瘤较小,Ki-67 细胞分数低于适应性/129。然而,适应性/B6 和适应性/129 中的肿瘤的致癌特性相似。适应性/B6 中富集了与免疫相关的途径,而适应性/129 中则没有。原位肿瘤的流式细胞术分析显示,适应性/B6 中的细胞毒性 CD8 T 细胞和单核细胞-髓样来源的抑制细胞分数高于适应性/129。适应性/B6 中的估计 CD8 和 CD4 细胞分数与人类 ATC 相似,但在原始/B6 中则可以忽略不计。
在 C57BL/6 小鼠中建立了一种新的 ATC 原位肿瘤模型。与原始 B6129SF1 小鼠模型相比,新型模型表现出更具侵袭性的肿瘤细胞行为和强烈的免疫反应。我们预计该新型模型有助于理解肿瘤微环境,并为药物开发提供平台。